Clinical Scorecard: Is MRI Essential for All Patients Without Prior Biopsy? Insights from a Multicenter Cohort Study
At a Glance
Category
Detail
Condition
Prostate cancer (PCA), clinically significant (csPCA) and non-significant (nsPCA)
Key Mechanisms
Use of multiparametric MRI with PI-RADS scoring combined with systematic biopsy (SB) and targeted biopsy (TB) for tumor detection and grading
Target Population
Biopsy-naïve men with suspected prostate cancer undergoing initial biopsy
Care Setting
Multicenter urology centers with access to MRI and biopsy facilities
Key Highlights
Combined biopsy (CB) using MRI-targeted biopsy plus systematic biopsy detects more clinically significant prostate cancer than either method alone.
MRI-targeted biopsy (TB) is more efficient per biopsy core but may miss some csPCA cases, especially in PI-RADS 3 lesions where SB detects more csPCA.
Negative predictive value of prostate MRI is heterogeneous; biopsy should not be omitted solely based on negative MRI results.
Guideline-Based Recommendations
Diagnosis
Use multiparametric MRI with PI-RADS scoring prior to biopsy in men with suspicious PSA, abnormal DRE, or abnormal TRUS findings.
Perform combined biopsy (CB) including both systematic biopsy (SB) and MRI-targeted biopsy (TB) to maximize csPCA detection.
Do not omit systematic biopsy in biopsy-naïve men even if MRI is negative due to variable negative predictive value.
Management
Consider individual risk assessment including PSA density, prostate volume, and clinical findings to guide biopsy approach.
In patients with high PSA (>20 ng/ml), combined biopsy remains superior for detection despite high csPCA prevalence.
Monitoring & Follow-up
Monitor biopsy outcomes with histopathological evaluation according to ISUP guidelines to confirm csPCA (Gleason ≥ 3+4).
Use PI-RADS scoring and clinical parameters to stratify patients for follow-up and further diagnostic procedures.
Risks
Technical limitations and inter-reader variability in MRI interpretation may lead to missed csPCA.
Complexity of MRI-targeted biopsy requires trained personnel and interdisciplinary communication, posing barriers to widespread access.
Relying solely on MRI-targeted biopsy risks underdiagnosis of csPCA, especially in PI-RADS 3 lesions.
Patient & Prescribing Data
Biopsy-naïve men with suspected prostate cancer and PI-RADS 3–5 lesions
Combined biopsy approach improves detection rates of clinically significant prostate cancer compared to single biopsy methods; MRI-targeted biopsy alone is insufficient to replace systematic biopsy.
Clinical Best Practices
Perform multiparametric MRI interpreted by board-certified radiologists using PI-RADSv2 prior to biopsy.
Use software-assisted fusion techniques for targeted biopsy combined with standardized 12-core systematic biopsy.
Ensure biopsy procedures are conducted by trained urologists or supervised residents with interdisciplinary communication.
Incorporate clinical parameters such as PSA, DRE, and PSA density in biopsy decision-making.
Maintain awareness of MRI limitations and do not omit biopsy based solely on negative MRI findings.
